Sequence assignments in partially replicate design [Design Issues]

posted by Loky do – Egypt, 2020-07-19 03:33 (1744 d 17:20 ago) – Posting: # 21746
Views: 3,773

Dears

In partially replicate 3-way design, FDA recommends using the following example for sequence assignments 1,2,3 --> (TRR, RTR, RRT), if we used different sequence assignments 1,2,3 --> (TRR, RRT, RTR), is this change significant? or is it ok as long as it's considered in statistical analysis?

Thanks in advance

Complete thread:

UA Flag
Activity
 Admin contact
23,424 posts in 4,927 threads, 1,673 registered users;
94 visitors (0 registered, 94 guests [including 1 identified bots]).
Forum time: 20:54 CEST (Europe/Vienna)

There are two possible outcomes: if the result confirms the
hypothesis, then you’ve made a measurement. If the result is
contrary to the hypothesis, then you’ve made a discovery.    Enrico Fermi

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5